Ep 90: SGLT-2 Inhibitors & What’s Next for Type 1 Diabetes: FDA’s Sotagliflozin Denial – with Stacey Simms
LISTEN TO THE EPISODE
- Sotagliflozin & SGLT Inhibitors in T1D: Why these medications matter and what the latest data shows.
- The FDA Denial: Understanding the DKA concerns and why approval remains challenging.
- Real-World Experience: How clinicians are using SGLT inhibitors safely today in select patients.
- Continuous Ketone Monitoring: Why dual-analyte sensors could unlock safer use in T1D.
- GLP-1s in Type 1 Diabetes: What recent research reveals about potential benefits.
- Who Might Benefit Most: Kidney protection, heart health, and metabolic improvements.
- Looking Ahead: How ongoing studies and patient advocacy could shape future guidelines.
Why did the FDA deny sotagliflozin —even with strong data showing heart, kidney, and glucose benefits? In this episode, Dr. Steve Edelman sits down with special guest Stacey Simms to break down the full story behind SGLT inhibitors and their complicated path in type 1 diabetes.
Together, they walk through how SGLT inhibitors transformed type 2 diabetes care, why many clinicians believe people with type 1 should have access, and how the risk of DKA shaped the FDA’s decision. Dr. Edelman also shares insights on who might benefit, how to reduce risk, and why continuous ketone monitoring could be a game-changer for future approvals.
They also touch on the growing discussion around GLP-1 medications in type 1 diabetes, new study results, and what emerging evidence could mean for future treatment options.
Leave a Reply